ArticleBMC medicine2026
Engineered iMSCs delivering wild-type IL-2 achieve dose-sparing tumor control via CD25-dependent CD8
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundInterleukin-2 (IL-2), the first FDA-approved cytokine-based immunotherapy, can induce durable antitumor responses but its broader use is curtailed by life-threatening, dose-dependent toxicities. This narrow therapeutic window has limited clinical translation for decades. Genetically engineered mesenchymal stromal cells (MSCs) have emerged as attractive IL-2 delivery vehicles due to their low immunogenicity and intrinsic tumor-homing capacity.
methodsHuman induced pluripotent stem cells (iPSCs) were edited by CRISPR/Cas9 to knock in wild-type IL-2 (wtIL-2) or a receptor-biased variant (IL-2v) into the B2M or B3 safe-harbor loci, generating cytokine-secreting iPSC-derived MSCs (iMSCs). Antitumor activity was evaluated in co-cultures of iMSCs, tumor cells, and peripheral blood mononuclear cells (PBMCs) by flow cytometry. In vivo, systemically administered iMSCs were tracked by live imaging in mice bearing subcutaneous tumors to assess biodistribution and tumor targeting. Tumor control was monitored by longitudinal tumor growth and end-point volume; toxicity was evaluated by lung wet weight and blood biochemistry. Immune cell states within the tumor microenvironment were characterized by flow cytometry and RNA sequencing. Data (mean ± s.e.m.) were analyzed in GraphPad Prism using t-tests, ANOVA, or Kruskal-Wallis tests, as appropriate (n = biological replicates; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001).
resultsSurprisingly, we found that under low-dose conditions, only iMSCs with IL-2 overexpression-but not unmodified iMSCs or free IL-2 alone-induced robust upregulation of CD25 on CD8
conclusionsThese findings point to a mechanism by which iMSC-delivered IL-2 reshapes the tumor microenvironment through CD25-dependent CD8⁺ T-cell activation. Furthermore, the results support the concept that this platform enables a more dose-efficient cytokine delivery strategy with an improved safety profile, thereby facilitating the clinical translation of off-the-shelf allogeneic iMSC-based gene therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.